BioStem Technologies, Inc.

BioStem Technologies, Inc. is a regenerative medicine company specializing in the development, manufacture, and commercialization of perinatal tissue allografts. The company's core mission is to produce life-changing products, aiming for excellence in the development and production of such innovations. Headquartered in Pompano Beach, Florida, BioStem Technologies has also secured land for a future headquarters in Boca Raton, Florida.

BioStem Technologies focuses on advanced wound care and regenerative therapies, leveraging its proprietary BioRetain® processing method to preserve the natural properties of perinatal tissue. Its product portfolio includes placental-derived allografts such as VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, AmnioWrap2™, Neox®, and Clarix®. These products are utilized across various market segments, including private offices, ambulatory surgery centers, hospitals, outpatient wound care centers, and federal healthcare systems like the VA and DoD.

Led by CEO and co-founder Jason Matuszewski, BioStem Technologies is actively pursuing growth and market expansion. Recent developments include the appointment of Katherine Gorrell as Chief Legal & Compliance Officer in April 2026 and the acquisition of BioTissue's surgical and wound care business in January 2026. The company is also preparing to release its first-quarter 2026 financial results in May 2026 and is working towards a Nasdaq uplisting to enhance its market presence and liquidity.